Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Theranexus    ALTHX   FR0013286259

THERANEXUS

(ALTHX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

THERANEXUS : EXTENDS THE CAPACITIES OF NEUROLEAD, ITS ASSET SCREENING PLATFORM, TO AUTOPHAGIA AND LYSOSOMAL NEUROLOGICAL DISEASES

03/10/2021 | 07:40am EDT

Lyon - Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, announces the extension of the capacities of NeuroLead, its discovery platform drug candidates, autophagy and neurologically expressed lysosomal diseases.

NeuroLead, which combines the latest innovations in neuroscience and artificial intelligence, is a platform for generating new drug candidates from a unique concept, the therapeutic targeting of interactions between glial and neuronal cells. By applying Neurolead to autophagy and to the neurological forms of lysosomal diseases, Theranexus is continuing its research on a therapeutic axis of major interest, presenting strong medico-economic challenges.

The common point of lysosomal diseases is a genetic deficiency leading to a malfunction of lysosomes cellular organelles responsible for the degradation of numerous biomolecules. With the drug candidate BBDF-101 in Batten disease, Theranexus is already working on a juvenile form of lysosomal disease which is characterized by the accumulation of lipoproteins in the brain.

The NeuroLead platform has already made it possible to develop and validate various cellular models for studying autophagy, the biological process of recycling biomolecules by lysosomes. Theranexus has thus identified, by screening, various drug structures capable of acting, by various pathways, on cellular autophagy and lysosome function. This work is also reinforced by complementary in silico approaches, combining artificial intelligence and research in massive databases, and offering a better characterization of the classes of structures identified.

'The results of this research, based on the use of our models of interactions between neurons and astrocytes in a pathological context, open up new avenues for discovering drugs that modulate autophagy . This work will enable us to strengthen the industrial value potential of our platform to provide solutions adapted to the strong needs of the many patients with lysosomal diseases. ' Specifies Mathieu Charveriat, Scientific Director of Theranexus.

'There are 50 varieties of lysosomal diseases that affect more than 3,000 adults and children in France. 150 new cases are diagnosed each year. These diseases lead to the appearance of lesions in various organs: bones, heart, lungs, liver, spleen, brain, etc. causing particularly serious and irreversible disorders. Today, there are only 14 advanced treatments in France for 11 lysosomal diseases which is very insufficient given that these diseases very often lead to multiple disabilities and are life threatening. We have a real need for new treatments to overcome these diseases. 'Adds Stephane Antolin, president of the Association Vaincre les Maladies Lysosomales.

ABOUT THERANEXUS

Founded in 2013, THERANEXUS is a clinical-stage biopharmaceutical company from CEA that develops drug candidates for the treatment of diseases of the nervous system.

Thanks to its knowledge of neuro-glial interactions, THERANEXUS is a pioneer in the design and combination of approved substances and has a solid and diversified portfolio of active ingredients in the clinical phase. This strategy of combining repositioned drugs based on a solid commercial case and having a real ability to quickly demonstrate their clinical value allows the company to generate different high value-added proprietary drug candidates, significantly reducing the time and costs of development and considerably increase the chances of market access for its drugs.

To this end, THERANEXUS is positioned in several indications, including Parkinson's disease and Batten disease, for which no treatment is currently available on the market.

Contact:

Tel: +33 (0) 1 53 67 36 70

Email: theranexus@actus.fr

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about THERANEXUS
04/07THERANEXUS  : 2020 full-year results and update on the progress of main programs
PU
04/07THERANEXUS  : 2020 full-year results and update on the progress of main programs
AN
04/07THERANEXUS  : Annual results
CO
03/10THERANEXUS  : Extends the capacities of neurolead, its asset screening platform,..
AQ
03/09THERANEXUS  : Theranexus extends the capabilities of neurolead, its active agent..
AN
01/22THERANEXUS  : presents an update on the progress of its main programs and announ..
PU
01/19THERANEXUS  : Provides an update on the progress of its main programs and announ..
AQ
01/18THERANEXUS  : Theranexus presents an update on the progress of its main programs..
AN
01/18THERANEXUS  : 4th quarter earnings
CO
2020THERANEXUS  : Publishes its 2021 financial agenda
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -3,40 M -4,05 M -4,05 M
Net Debt 2020 - - -
P/E ratio 2020 -9,16x
Yield 2020 -
Capitalization 50,9 M 60,6 M 60,5 M
Capi. / Sales 2020 -
EV / Sales 2021 2,75x
Nbr of Employees 17
Free-Float 70,1%
Chart THERANEXUS
Duration : Period :
Theranexus Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERANEXUS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 25,50 €
Last Close Price 13,74 €
Spread / Highest target 162%
Spread / Average Target 85,6%
Spread / Lowest Target 45,6%
EPS Revisions
Managers and Directors
NameTitle
Franck Joseph Louis Mouthon Chairman & Chief Executive Officer
Thierry Bertrand Lambert Chief Financial & Administrative Officer
Mathieu Bernard Mari Charveriat Director, Chief Scientific Officer & Deputy CEO
Werner Rein Chief Medical Officer
Dominique Costantini Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERANEXUS-26.33%61
GILEAD SCIENCES, INC.11.76%81 411
VERTEX PHARMACEUTICALS INCORPORATED-9.62%55 284
WUXI APPTEC CO., LTD.-1.48%49 513
REGENERON PHARMACEUTICALS, INC.-1.64%49 239
BIONTECH SE49.07%29 350